Raghuraman Srinivasan, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 450a Tucker Dr, Maysville, KY 41056 Phone: 606-759-0339 Fax: 606-759-0139 |
Eric R. Lohman, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 901 Kenton Station Dr, Maysville, KY 41056 Phone: 606-759-9353 Fax: 606-759-9702 |
News Archive
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Increased brain cell apoptosis in intrauterine growth-restricted fetal rats is a key reason for unfavorable long-term prognosis of the nervous system. The harmful effects of intrauterine growth restriction on fetal brain development originate in the womb.
News outlets set the scene for President Barack Obama's meeting today with lawmakers. Both sides say they want a deal, but privately, some Democrats acknowledge they would rather go over the cliff than accept a deal that raised too few taxes while cutting Medicare and Medicaid. Some Republicans feel that way about tax increases.
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
› Verified 7 days ago